SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Ando T, Ishiguro H, Kimura M, Mitsui A, Mori Y, Sugito N, Tomoda K, Mori R, Harada K, Katada T, Ogawa R, Fujii Y, Kuwabara Y. 2007. The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol Rep 18: 601619.
  • Bilderback TR, Gazula VR, Lisanti MP, Dobrowsky RT. 1999. Caveolin interacts with Trk A and p75 (NTR) and regulates neurotrophin signaling pathways. J Biol Chem 274: 257263.
  • Cantiani L, Manara MC, Zucchini C, De Sanctis P, Zuntini M, Valvassori L, Serra M, Olivero M, Di Renzo MF, Colombo MP, Picci P, Scotlandi K. 2007. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res 67: 76757685.
  • Carver LA, Schnitzer JE. 2003. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 3: 571581.
  • Cavallaro U, Christofori G. 2004. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4: 118132.
  • Cho DS, Yim H, Cho KS, Hong SJ, Cho NH, Kim SI, Ahn HS, Kim SJ. 2008. Impact of caveolin-1 expression on the prognosis of transitional cell carcinoma of the upper urinary tract. J Korean Med Sci 23: 296301.
  • Conde MC, Ramirez-Lorca R, Lopez-Jamar JM, Molero E, Ramírez-Armengol JA, Moreno Nogueira JA, Pascual MH, Ruiz A, Martín-Cordova CG, Real LM, Royo JL. 2006. Genetic analysis of caveolin-1 and eNOS genes in colorectal cancer. Oncol Rep 16: 353359.
  • Davidson B, Nesland JM, Goldberg I, Kopolovic J, Gotlieb WH, Bryne M, Ben-Baruch G, Berner A, Reich R. 2001. Caveolin-1 expression in advanced-stage ovarian carcinoma—a clinicopathologic study. Gynecol Oncol 81: 166171.
  • Del Galdo F, Lisanti MP, Jimenez SA. 2008. Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 20: 713719.
  • Dormán G, Kocsis-Szommer K, Spadoni C, Ferdinandy P. 2007. MMP inhibitors in cardiac diseases: an update. Recent Patents Cardiovasc Drug Discov 2: 186194.
  • Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, Lisanti MP. 1998. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in-vivo. FEBS Lett 428: 205211.
  • Fiucci G, Ravid D, Reich R, Liscovitch M. 2002. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness inMCF-7 human breast cancer cells. Oncogene 21: 23652375.
  • Galbiati F, Volonte D, Brown AM, Weinstein DE, Ben-Ze'ev A, Pestell RG, Lisanti MP. 2007. Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem 275: 2336823377.
  • Glait C, Tencer L, Ravid D, Sarfstein R, Liscovitch M, Werner H. 2006. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1-and p53-dependent pathways. Exp Cell Res 312: 38993908.
  • Goetz JG, Lajoie P, Wiseman SM, Nabi IR. 2008. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 27: 715735.
  • Grande-García A, Del Pozo MA. 2008. Caveolin-1 in cell polarization and directional migration. Eur J Cell Biol 87: 641647.
  • Gumbiner B, Stevenson B, Grimaldi A. 1998. The role of the cell adhesion molecule uvomorulin in the formation and maintenance of the epithelial junctional complex. J Cell Biol 107: 15751587.
  • Hayashi K, Matsuda S, Machida K. 2001. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61: 23612364.
  • Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Ratschiller D, Gugger M, Donovan M, Lasek A, Rickert P. 2002. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 21: 77497763.
  • Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ. 1987. A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 38: 137147.
  • Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, König H, Weg-Remers S, Ponta H. 2000. CD44 acts as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci 910: 106118.
  • Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. 2002. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 161: 16471656.
  • Hynes RO. 1992. Integrins versatility, modulation, and signaling in cell adhesion. Cell 69: 1125.
  • Johnson BE, Grayson J, Makuch RW, Linnoila RI, Anderson MJ, Cohen MH, Glatstein E, Minna JD, Ihde DC. 1990. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol 8: 396401.
  • Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H. 2002. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94: 929933.
  • Kemler R. 1993. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 9: 317321.
  • Liu HX, Xing LX, Wang HB, Yang JQ, Sun YM. 2008. Relationship between expression of caveolin-1 and pERK1/2 and prognosis in non-small cell lung cancer. Zhonghua Bing Li Xue Za Zhi 37: 615619.
  • Lu Z, Ghosh S, Wang Z, Hunter T. 2003. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499515.
  • Mann A, Breuhahn K, Schirmacher P, Wilhelmi A, Beyer C, Rosenau A, Ozbek S, Rose-John S, Blessing M. 2001. Up-and down-regulation of granulocyte/macrophage-colony stimulating factor activity in murine skin increase susceptibility to skin carcinogenesis by independent mechanisms. Cancer Res 61: 23112319.
  • Miotti S, Tomassetti A, Facetti I, Sanna E, Berno V, Canevari S. 2005. Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases. Am J Pathol 167: 14111427.
  • Moon KC, Lee GK, Yoo SH, Jeon YK, Chung JH, Han J, Chung DH. 2005. Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Res 25: 46314637.
  • Mouraviev V, Li L, Tahir SA, Yang G, Timme TM, Goltsov A, Ren C, Satoh T, Wheeler TM, Ittmann MM, Miles BJ, Amato RJ, Kadmon D, Thompson TC. 2002. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 168: 15891596.
  • Qi BJ, Zheng YM, Liu X, Sun H, Li F. 2008. The impacts of stable transfected caveolin-1 on the cell cycle distribution in breast cancer cell line Hs578/DOX. Bull Chin Cancer 17: 5254.
  • Sahai E. 2005. Mechanisms of cancer cell invasion. Curr Opin Genet 15: 8796.
  • Salani B, Briatore L, Garibaldi S, Cordera R, Maggi D. 2008. Caveolin-1 down-regulation inhibits insulin-like growth factor-I receptor signal transduction in H9C2 rat cardiomyoblasts. Endocrinology 149: 461465.
  • Schlott T, Eiffert H, Bohne W, Landgrebe J, Brunner E, Spielbauer B, Knight B. 2005. Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue. Gynecol Oncol 98: 409419.
  • Selga E, Morales C, Noé V, Peinado MA, Ciudad CJ. 2008. Role of caveolin 1, E-cadherin, enolase 2 and PKC alpha on resistance tomethotrexate in human HT29 colon cancer cells. BMC Med Genomics 1: 35.
  • Shapiro L, Fannon AM, Kwong PD, Thompson A, Lehmann MS, Grübel G, Legrand JF, Als-Nielsen J, Colman DR, Hendrickson WA. 1995. Structural basis of cell-cell adhesion by cadherins. Nature 374: 327337.
  • Sotgia F, Rui H, Bonuccelli G, Mercier I, Pestell RG, Lisanti MP. 2006. Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res 66: 1064710651.
  • Stahlhut M, Deurs BV. 2000. Identification of filamin as a novel ligand for caveolin-1: evidence for the organization of caveolin-1-associated membrane domains by the actin cytoskeleton. Mol Biol Cell 11: 325337.
  • Strumane K, Van Roy F, Berx G. 2003. The role of E-cadherin in epithelial differentiation and cancer progression. Recent Res Dev Cell Biochem 1: 3337.
  • Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD, Shay JW, Gazdar AF, Minna JD. 2004. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 64: 42774285.
  • Thomas NB, Hutcheson IR, Campbell L, Gee J, Taylor KM, Nicholson RI, Gumbleton M. 2009. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat (in press).
  • Torres VA, Tapia JC, Rodriguez DA, Lladser A, Arredondo C, Leyton L, Quest AF. 2007. E-cadherin is required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced beta-catenin-Tcf/Lef-dependent transcription. Mol Cell Biol 27: 77037717.
  • Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, Lisanti MP. 2004. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 279: 5163051646.
  • Witkiewicz AK, Nguyen KH, Dasgupta A, Kennedy EP, Yeo CJ, Lisanti MP, Brody JR. 2008. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle 7: 30213025.
  • Yamamoto M, Toya Y, Jensen RA, Ishikawa Y. 1999. Caveolin is an inhibitor of platelet-derived growth factor receptor signaling. Exp Cell Res 247: 380388.
  • Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. 1998. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 18731880.
  • Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, Lee SD, Choi YL, Kim MK, Chung DH. 2003. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 42: 195202.
  • Yu JH, Wei Q, Qi FJ. 2006. Significance of caveolin-1 expression in primary lung cancer. Zhonghua Bing Li Xue Za Zhi 35: 664668.